Marcus F Keep

US Patent:

7446093, Nov 4, 2008

Filed:

Feb 26, 2000

Appl. No.:

09/674092

Inventors:

Marcus Keep - Honolulu HI, US
Eskil Elmer - Lund, SE

Assignee:

Maas BiolAB, LLC - Albuquerque NM

International Classification:

A61K 38/12
A61K 38/00

US Classification:

514 9, 514 11, 530317

Abstract:

A cyclosporin-containing pharmaceutical preparation for cerebrospinal or vascular application is disclosed, comprising (1) at least one cyclosporin, and (2) DMSO.

US Patent:

20040147433, Jul 29, 2004

Filed:

Jan 15, 2004

Appl. No.:

10/757533

Inventors:

Marcus Keep - Honolulu HI, US
Eskil Elmer - Lund, SE

International Classification:

A61K038/13

US Classification:

514/011000

Abstract:

Method for selectively reducing mammal neuron damage or death in neuroimmunophilin-rich neurons of central, peripheral, and autonomic nervous systems of a mammal while not reducing damage or death to neuroimmunophilin-poor cells and tissues selected from the group consisting of glia, glia-derived tumor cells, abnormal neuron-derived tumor cells, non-brain tumors, and non-neuron tissue of the body from ionizing radiation. The method includes preparing a dosage of a neuroimmunophilin ligand selected from the group consisting of cyclosporins and functional derivatives, metabolites, variants, and salts thereof which are able to cross the blood-brain barrier. The dosage is from an effective amount to less than 1 gr/kg of body weight of said mammal. The method includes the step of administering that dosage to the mammal before, co-incident with, or after ionizing radiation of the mammal. The dose is administered the same day as, but not later than one week after, last radiation exposure.

US Patent:

59729244, Oct 26, 1999

Filed:

Jul 11, 1997

Appl. No.:

8/860898

Inventors:

Marcus Floyd Keep - Honolulu HI
Eskil Mats Elmer - Lund, SE
Merab Kokaia - Lund, SE
Hiroyuki Uchino - Tokyo, JP
Zaal Kokaia - Lund, SE
Hakan Widner - Lund, SE
Qi Zhao - Sunnyvale CA
Keiko Uchino - Tokyo, JP

Assignee:

Maas BiolAB, LLC - Honolulu HI

International Classification:

A61K 3133

US Classification:

514183

Abstract:

The invention provides pharmaceutical compositions and medications useful for the treatment of cerebral ischernia, cerebral insult, and cerebral disorders using the active treatment medication cyclosporin A, variants or pharmaceutically acceptable derivatives thereof, inconditions, situations and methods wherein the blood-brain barrier has been opened, disrupted, bypassed, transgressed, obviated or crossed,such that cyclosporin A, variants or pharmaceutically acceptable derivatives thereof come into contact with neurons and neuron support cells. Included in the invention are methods for the use of the said pharmaceutical compositions and medications. Also included in the invention are conditions, situations and methods whereby the active treatment medication can come in contact with neurons and neuron support cells.